Search results for "Cirrhosis"


 
Results 111 - 120 of about 123 for "Cirrhosis".
Sort by: Relevance | Newest | Oldest

New HCV drug combo approved

The fixed-dose tablet combines the previously approved drugs sofosbuvir and velpatasvir with a new drug, voxilaprevir.
https://gastroenterology.acponline.org/archives/2017/07/28/10.htm
28 Jul 2017

NAFLD practice guidance issued for screening, treatment

The guidance, from the American Association for the Study of Liver Diseases, notes that routine screening for nonalcoholic fatty liver disease (NAFLD) in a primary care setting or obesity clinics is not typically recommended due to uncertainties in long-term benefits and cost-effectiveness.
https://gastroenterology.acponline.org/archives/2017/07/28/2.htm
28 Jul 2017

Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response

A commentary in ACP Journal Club noted that while screening and treating all patients with chronic hepatitis C virus (HCV) would be cost-effective and probably cost-saving, some payers are still resistant.
https://gastroenterology.acponline.org/archives/2017/07/28/11.htm
28 Jul 2017

Cirrhosis associated with increased risk of stroke, study finds

Researchers performed a retrospective cohort study using a random 5% sample of more than 1.6 million inpatient and outpatient Medicare claims from Jan. 1, 2008, through Dec. 31, 2014.
https://gastroenterology.acponline.org/archives/2017/06/23/2.htm
23 Jun 2017

HCV treatment appeared successful for patients who hadn't responded to previous direct-acting antivirals, industry-funded study finds

The study included two phase 3 trials: POLARIS-1, in which patients with chronic hepatitis C virus (HCV) had previously taken a regimen containing an NS5A inhibitor, and POLARIS-4, in which patients had previously received a direct-acting antiviral agent regimen that did not include an NS5A inhibitor.
https://gastroenterology.acponline.org/archives/2017/06/23/3.htm
23 Jun 2017

Anticoagulants safe, effective in cirrhosis with portal vein thrombosis, review finds

Researchers analyzed eight studies with 353 patients to assess the effect of low-molecular-weight heparin or warfarin on recanalization, thrombosis progression, and bleeding.
https://gastroenterology.acponline.org/archives/2017/05/26/3.htm
26 May 2017

Spotlight on statin therapy

Studies published in May found a potential benefit of statin therapy for three different conditions.
https://gastroenterology.acponline.org/archives/2017/05/26/5.htm
26 May 2017

Risk of liver-related death linked to increased fibrosis stage in NAFLD

The systematic review and meta-analysis included five studies of 1,495 adult patients with nonalcoholic fatty liver disease (NAFLD), encompassing 17,452 patient-years of follow-up.
https://gastroenterology.acponline.org/archives/2017/04/28/2.htm
28 Apr 2017

Pioglitazone associated with improved advanced fibrosis in patients with NASH

A recent meta-analysis looked at randomized clinical trials that examined the effect of thiazolidinediones on liver histology in patients with nonalcoholic steatohepatitis (NASH).
https://gastroenterology.acponline.org/archives/2017/03/24/1.htm
24 Mar 2017

High HCV cure rate seen with FDA-approved direct-acting antiviral regimens

Six of the direct-acting antiviral (DAA) regimens yielded sustained virologic response rates above 95% in patients who had hepatitis C virus (HCV) genotype 1 without cirrhosis, including those with HIV co-infection.
https://gastroenterology.acponline.org/archives/2017/03/24/7.htm
24 Mar 2017

Result Page: Prev   7   8   9   10   11   12   13   Next